Medtronic lifts FY26 outlook amid 50% growth in cardiac ablation
The Ireland-headquartered medtech giant's total sales reached $8.57bn in Q1 FY26, corresponding to an 8.4% rise on Q1 of FY25, which came in at $7.9bn. Medtronic now expects adjusted profits for FY26 to fall between $5.60 and $5.66 per share, up from $5.50 to $5.60 previously.
Barring speciality therapies within its neuroscience portfolio, Medtronic achieved single-digit growth across all of its product lines. Cardiovascular was the company's strongest performing segment in FY26, with worldwide profits of $3.28bn, reflecting growth of 9.3% from around $3bn compared to the same period in the previous fiscal year.
Cardiac Rhythm & Heart Failure witnessed the highest growth within Medtronic's cardiovascular portfolio, climbing to around $1.7bn, denoting an 11.5% rise on $1.53bn in Q1 of FY25.
The uplift reflects the ongoing adoption of Medtronic's Affera mapping and ablation system featuring the Sphere-9 Catheter, and PulseSelect PFA for the treatment of atrial fibrillation (AFib). The systems gained US Food and Drug Administration (FDA) clearance in December 2023 and October 2024, respectively.
Medtronic CEO Jeff Martha revealed in a post-earnings conference call that in Q1 of FY26, the company reached nearly 50% growth in cardiac ablation solutions on the rollout of its PFA systems.
'This performance is reflective of our execution capabilities, and we're excited that our growth momentum in this pivotal area is only just beginning,' Martha said.
'Looking this past quarter, I've witnessed Fara [Boston Scientific's Farapulse PFA system] and our competitors in action in several ablation cases, and I can tell you firsthand that the advantages that we're bringing to the market in terms of procedure time and ease of use are truly differentiated.'
Martha added that physician feedback and utilisation levels of Medtronic's PFA equipment had been 'phenomenal', stating that the company now has 'more conviction than ever' that it has the right technology and product pipeline in place to progress towards a leadership position in cardiac ablation.
In July, Boston Scientific's Q2 2025 financials revealed even stronger performance in its cardiovascular unit, with profits of $3.34bn, representing a 26.8% increase on the unit's Q2 2024 performance at $2.63bn.
According to GlobalData analysis, months after separate approvals for Farapulse and PulseSelect, physicians in the US had already started displaying a much stronger preference for Boston's product over Medtronic's.
Johnson and Johnson (J&J) received FDA approval for its Varipulse PFA system in 2024. In its Q2 2025 financials, J&J reported a 7.3% rise in its Medtech unit in Q2 2024 to around $8.54bn.
Medtronic also lifted its FY2026 outlook due to a lower-than-expected impact from US President Donald Trump's tariffs. The company has revised the assumed impact of tariffs to $185m for the fiscal year, down from $200m to $350m previously. The move aligns with other recent tariff impacted revenue trims by companies including Zimmer Biomet and Philips.
"Medtronic lifts FY26 outlook amid 50% growth in cardiac ablation" was originally created and published by Medical Device Network, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
21 minutes ago
- Yahoo
Arsenal's ruthless Eze coup shows intent
Arsenal's dramatic move to steal Eberechi Eze away from arch-rivals Tottenham Hotspur is a ruthless statement of intent designed to show this is the season they plan to finally claim the biggest prizes. Spurs were ready to roll out the welcoming carpet for Crystal Palace's England forward on Wednesday, the deal virtually done with every indication the 27-year-old was set on the move. It then filtered out that Arsenal were assessing the seriousness of a knee injury to forward Kai Havertz, which could potentially put a dent in their attacking resources - a weakness that played a significant part in manager Mikel Arteta's side ending empty handed for the fifth year in succession last season. Instead of taking the cheaper option of exploring the loan market, as was first expected, Arsenal went for broke in spectacular style by setting up a £60m coup to take Eze to Emirates Stadium from right under the noses of Spurs. Eze's move to Arsenal, which is now fully expected to be successfully concluded, is not simply a devastating psychological blow aimed across north London at Spurs. It is a clear signal that they have no intention of falling short in their stated aim of mounting a serious Premier League title challenge, as well as making inroads deep into the Champions League once more after reaching the semi-final last season. It is strategy in stark contrast to the inertia that gripped Arsenal last season, when their failure to solve an obvious problem - namely sign a recognised striker - cost them dearly. Spurs thought they had Eze wrapped up, the possibility of a cash-plus-Richarlison deal discussed, but Arsenal moved with lightning speed once they were confronted by the possibility of Havertz facing a spell on the sidelines. Arsenal have been linked with Eze all summer, but it was thought their interest had cooled once Ethan Nwaneri agreed a new five-year contract, on top of signing Chelsea winger Noni Madueke in a £48.5m deal. Havertz's injury, and its potential consequences, reignited that interest to leave Spurs stunned. Arsenal move ahead of Spurs in race for £60m Eze Football Daily: Isak's social statement & who else is on the move? Arteta knows this is the season he must land a major prize, and to do this he has been heavily backed by Arsenal's hierarchy. As well as Madueke, the Gunners have concluded moves to sign Spain's outstanding midfield man Martin Zubimendi in a deal worth up to £60m and, at least 12 months too late, a recognised striker in Viktor Gyokeres, signed from Sporting Lisbon for £64m. In Eze, who had two years left on his Palace contract, Arsenal will get a versatile forward rich in natural talent who is a match-winner - as he proved when scoring the winner against Manchester City in the FA Cup final in May. This was a follow-up to the spectacular right-foot finish that set Palace on their way to a 3-0 win over Aston Villa at Wembley in the semi-final. Eze also scored the Eagles' opener when they beat Fulham 3-0 at Craven Cottage in the quarter-final. Eze has demonstrated he has the temperament and talent for the big occasion when inspiring Palace to the first major trophy in their history. Arsenal will hope he has plenty of those occasions ahead. He is a scorer and creator of goals, adding real threat to Arsenal's front line, with 14 goals in all competitions last season. Eze was a boyhood Arsenal fan and was part of the club's academy until he was 13. He may have been initially keen on a move to Spurs, but once the Gunners showed their hand was only one part of north London he was heading to. He has achieved his goals the hard way, spending time at Fulham, Reading and Millwall before signing for Queen's Park Rangers. He left Loftus Road for Palace in a £19.5m deal in August 2020. Spurs believe they did all they could to conclude a deal - apart from actually concluding it - but it is a hammer blow to chairman Daniel Levy and manager Thomas Frank, who also thought they had a deal for Morgan Gibbs-White in the bag only for him to sign a new contract at Nottingham Forest. Arsenal will revel in the local rivalry of snatching away a prime transfer target for Spurs, but the wider context demonstrates the Gunners are deadly serious about ending the wait for success that now stretches back to 2020. Eze has previously admitted to "crying for a week" when he was let go by Arsenal in 2011, but this gifted forward has now been given a golden opportunity to make up for lost time. Latest Arsenal news, analysis and fan views Ask about Arsenal - what do you want to know?
Yahoo
21 minutes ago
- Yahoo
Basilea Pharmaceutica Ltd (BPMUF) (H1 2025) Earnings Call Highlights: Strong Revenue Growth and ...
This article first appeared on GuruFocus. Global In-Market Sales Increase: Procemba sales increased by 24.8% for the 12-month period ending March 2025. Royalty Income Growth: 21.7% year-on-year increase in royalty income. Operating Result: Positive operating result of CHF 24 million for the first six months of 2025. Additional Funding: Secured $39 million in non-dilutive funding from BAA. Revenue: Total revenue of CHF 104 million, a 36% increase compared to the first half of 2024. Operating Expenses: CHF 55.7 million, mainly due to costs associated with the ongoing phase 3 program. Net Profit: CHF 15.8 million, compared to CHF 20.7 million in the first half of 2024. Net Cash Position: Positive net cash position of CHF 50.7 million as of June 30, 2025. Operating Cash Flow: Positive cash flow of CHF 23.1 million from operating activities. Debt Reduction: Reduced total debt by CHF 138.3 million from 2022 through June 30, 2025. Full Year 2025 Guidance: Total revenue expected to increase by about 8% to CHF 225 million. R&D Expenses: Projected to rise to CHF 105 million for 2025. Operating Profit Guidance: Expected operating profit of approximately CHF 50 million for 2025. Warning! GuruFocus has detected 5 Warning Signs with BPMUF. Is BPMUF fairly valued? Test your thesis with our free DCF calculator. Release Date: August 19, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Basilea Pharmaceutica Ltd (BPMUF) reported a strong financial performance for the first half of 2025, with a positive operating result of CHF 24 million. The company's leading commercial product, Procemba, saw a 24.8% increase in global in-market sales, contributing to a 21.7% year-on-year increase in royalty income. Basilea secured an additional $39 million in non-dilutive funding from BAA to support the development of its antifungal candidates. The company successfully launched its antibiotic Zayra in the US through a partnership with Innoviva Specialty Therapeutics. Basilea expanded its portfolio by in-licensing ceftibutin deaborbactam, a phase 3 ready novel oral antibiotic for complicated urinary tract infections. Negative Points The net profit for the first half of 2025 decreased to CHF 15.8 million from CHF 20.7 million in the first half of 2024, due to a one-time income tax benefit in the previous year. The company anticipates a 17% reduction in product revenue to about CHF 48 million year-on-year due to a decrease in product supply to Pfizer. R&D expenses are projected to rise to CHF 105 million, driven by the in-licensing transaction and associated costs. The phase 3 program for the newly in-licensed antibiotic is expected to start in approximately 18 months, which may delay potential revenue contributions. Currency fluctuations, particularly the devaluation of the US dollar against the Swiss franc, impacted financial results. Q & A Highlights Q: Why is there an 18-month delay before starting the phase 3 trial for the newly in-licensed antibiotic? Does this relate to securing additional funding? A: David Veitch, CEO, clarified that the delay is not due to funding issues. The 18-month period is necessary for regulatory interactions with health authorities and operational setup. Marc Engelhardt, CMO, added that the studies require a large patient supply, which takes time to prepare. Q: How does the expanded access program for fosmanogepix impact regulatory approval, given the large number of patients involved? A: Marc Engelhardt, CMO, explained that the data from the expanded access program could serve as confirmatory evidence in an NDA filing, provided it meets FDA guidelines for completeness and context. Q: How does the new oral antibiotic fit into the treatment landscape for complicated UTIs, which is dominated by IV treatments? A: Marc Engelhardt, CMO, stated that the oral antibiotic will serve both as an initial empirical therapy and a step-down treatment from IV antibiotics, offering flexibility in hospital and outpatient settings. Q: Why is there expected softness in product revenues in the second half of the year? A: Adesh Kaul, CFO, explained that the fluctuation is due to product delivery schedules and initial supplies related to the US launch and other markets, rather than any underlying weakness. Q: What factors could accelerate enrollment in the fosmanogepix phase 3 program? A: Marc Engelhardt, CMO, mentioned that geographic analysis and increased sponsor engagement at underperforming sites could enhance enrollment rates. Q: Can you provide details on the sales and marketing infrastructure for Zevtera's US rollout? A: David Veitch, CEO, highlighted that Innoviva Specialty Therapeutics has extensive experience in launching antibiotics, with a comprehensive US coverage including sales, medical affairs, and access teams. Q: How does the oral antibiotic compare to GSK's oral carbapenem in clinical development for complicated UTIs? A: Marc Engelhardt, CMO, noted that while there are similarities in trial design, the new antibiotic offers advantages in spectrum and dosing frequency, potentially capturing significant market share. Q: How is Crescemba performing in the APAC region, and how will it mitigate the impact of the 2027 loss of exclusivity? A: Adesh Kaul, CFO, reported strong growth in APAC, particularly in Japan, where exclusivity extends beyond 2027, contributing to sustained revenue despite upcoming patent expirations. For the complete transcript of the earnings call, please refer to the full earnings call transcript. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Fast Company
23 minutes ago
- Fast Company
A creative's guide to community-building
I grew up on different continents—Africa, Europe, and North America. Having the privilege of living in and experiencing diverse countries and cultures during my formative years made it clear to me that, while we are all unique in many ways, there are still core things that are universal. We all want to nurture and spend time with our families. We all want to have fulfilling careers and to feel safe. We all value community. That last shared sentiment is at the center of a brand purpose trend that has remained largely resilient, despite some who claim otherwise. Studies show that we're still in an era where people not only demand brands that reflect their values, but show a deep commitment to a communalcause. We want brands to create change that makes our lives better, not just make a healthy profit. These alignments are areas where brands can lean in, promote belonging, and foster unity at a time of growing divisiveness. Creatives can be valuable partners in this, too—lending brands their insight as well as design, advertising, and strategic expertise. But only if we properly value and nurture their rich spectrum of lived experiences, encouraging the unique qualities that make creatives essential to cultivating a sense of togetherness. That's why, as community-building becomes the new imperative, we must provide creatives with environments that not only celebrate their work, but their individual voices and points of view. Community from creativity Creativity is more than a tool for messaging and communication. Its impact can transcend business into culture, helping us see the world in exciting new ways. And when you choose to be a creative, you're joining a community with its own codes and way of operating. Being in a creative community necessitates a willingness to contribute, participate, and add/realize value for everything from a group of people to an entire industry. As importantly, creative communities tend to have a diversity of perspective that results in more provocative ideas built from lived experiences and unique insights. For example, in working on a community engagement-focused campaign for Delta Air Lines, alongside their in-house agency and graduates from D&AD Shift—our night school for self-taught creatives—I was often surprised by the unexpected ideas shared by our incredible talent. They're a part of so many different subcultures, spread across the worlds of music, fashion, comedy, and more. And they are navigating their differences while developing their own community, making them experts at helping brands do the same. That ability to turn diverse perspectives into shared purpose is rare—especially post-COVID—and it's a quality that must be protected as countless influences increasingly drive us apart. Build a better community The best creative communities don't just happen. They're designed with intention, and they're given the clarity, investment, and support needed to thrive. In my work at Kin and D&AD, I've seen that, for creative people, prioritizing community-building means cultivating a safe space to share, debate, and discuss ideas. That takes prioritizing several core principles: Embrace people as they are: Pioneering creatives can come from any cultural or economic background and be at any stage of their careers. Low-cost tools and social media have also given birth to a generation of self-taught creatives with an entirely different life experience. Celebrate their unique personalities and perspectives. It's their ability to use their insights to notice and address challenges that create value. Recognize and affirm progress: While making room for acknowledgement may seem like something that should be a secondary concern, it's actually key to motivating and inspiring achievement. Incremental changes, consistently executed, lead to massive gains. Both deserve a nod when working with creatives. Positive friction is creative fuel: There's nothing wrong withdisagreement when it's structured and done respectfully. In fact, it's entirely expected when different perspectives come together around creative work. Lively conversation, debate, and collaboration create camaraderie and a sense of shared ownership of creative ideas, elevating them to more potent outcomes. Treat failure as R&D: That meanscelebrating risk-taking and losses as essential parts of the creative journey. They are the building blocks of innovative ideas, important signs that you're experimenting with something interesting and on the path to inventing something original, as long as you learn and evolve from them. Creatives need more environments that wholehearted embrace these principles, giving them a foundation that enhances community-building potential. That way, as brands and organizations increasingly leverage community-based approaches, they'll do so more authentically and in ways that add value to businesses and the broader culture.
